Melbourne, Australia: Starpharma today released its annual report and financial results for the year ended 30 June 2020.

2GB radios Jim Wilson interviewed Starpharma CEO Dr Jackie Fairley to get an update on how Starpharma is fast-tracking a nasal spray designed to be used as a preventative measure in the fight against COVID-19.

To listen to the full interview click here.

Starpharma was recently featured in an article by Australian Manufacturing, a leading publication and resource for the manufacturing and industrial sector in Australia. The article noted Starpharma had undertaken a pilot manufacture for its SPL7013 antiviral nasal spray, which has been tested and confirmed to have potent antiviral activity against SARS-CoV-2, the virus that causes COVID-19. The article also highlightsed SPL has identified a manufacturer and are currently compiling documentation in preparation for regulatory submission.

To read the full article click here.

Starpharma was featured on ABC’s  finance news segment ‘The Kohler Report’, where Alan Kohler highlighted that Starpharma shares had risen 23% following the Company’s update on its SPL7013-based antiviral nasal spray, which has shown to have potent antiviral activity against COVID-19. The update included that Starpharma has commenced confidential commercial discussions with related parties.

To watch the full report, click here.

Starpharma today announced progress with development, regulatory and manufacturing activities associated with a nasal spray for protection against COVID-19 based on the company’s proprietary antiviral dendrimer, SPL7013.

Starpharma today announced that it has signed a new research partnership with leading Chinese Pharmaceutical company Tianjin Chase Sun Pharmaceutical Co., Ltd. (stock code 300026; Chase Sun), to develop several DEP^® nanoparticle formulations for an anti-infective drug. The agreement also provides for the potential to conduct additional DEP^® programs, which can be across therapeutic areas beyond anti-infectives.